Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 603.1% in September

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 652,500 shares, an increase of 603.1% from the August 31st total of 92,800 shares. Approximately 36.9% of the company’s stock are short sold. Based on an average daily trading volume, of 714,300 shares, the short-interest ratio is presently 0.9 days.

Monopar Therapeutics Trading Up 17.2 %

Monopar Therapeutics stock traded up $0.76 during midday trading on Wednesday, hitting $5.17. The stock had a trading volume of 2,309,570 shares, compared to its average volume of 639,567. The business has a fifty day moving average price of $2.03 and a 200 day moving average price of $1.17. Monopar Therapeutics has a 12 month low of $1.37 and a 12 month high of $8.65. The stock has a market cap of $18.20 million, a P/E ratio of -9.98 and a beta of 1.16.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). On average, equities analysts anticipate that Monopar Therapeutics will post -1.93 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on shares of Monopar Therapeutics from $2.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.